Endomedix

Endomedix, Inc. is a medical device company founded in 2005 by John Abrahams, with Richard Russo currently serving as CEO. The company specializes in developing hydrogel technology solutions for the medical device market, focusing on biosurgery products. It operates in the tissue sealant, hemostat, and biomedical adhesive markets, with applications in various types of surgery and wound care.

The company's core business revolves around its patented tunable platform technology used to create a pipeline of engineered biosurgery devices. A key product is the PlexiClot™ Absorbable Hemostat, a liquid chemistry sprayed during neurosurgery that forms a structured hydrogel device in seconds. This product aims to control bleeding in brain and spinal procedures, a market estimated at $1.9 billion, by providing a new mechanism of action that improves upon the standard of care established in 1945. PlexiClot is designed to form a stable clot more rapidly without applying dangerous pressure to sensitive tissues.

Endomedix's business model is centered on developing and bringing to market devices that not only address unmet clinical needs but also offer cost savings to healthcare providers by reducing complications and re-operations. The company has secured multiple patents for its technology and has been actively raising capital to fund its development and clinical trials. It has raised a total of $1.99 million over several funding rounds, with investors including Central Texas Angel Network and Healthcare Ventures. The company is preparing to bring its PlexiClot™ device to market, supported by recent patents from the European Patent Office and grants for crucial animal trials.

Keywords: hydrogel technology, biosurgery devices, surgical hemostat, neurosurgery, medical device, tissue sealant, wound care, PlexiClot, biopolymers, absorbable hemostat